TNBC is a specific subtype of BC characterized by lack of expression of the three most targeted biomarkers in BC treatment: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER-2) [2,6]. Here, PGR is linked to breast cancer.